Published in Haemophilia on March 01, 2005
International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica (2009) 3.63
Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood (2012) 1.57
Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol (2011) 1.09
Ineffective off-label use of recombinant activated factor VII in a case of bone-marrow transplantation-related gastrointestinal bleeding. Thromb J (2006) 0.90
The utility of recombinant factor VIIa as a last resort in trauma. World J Emerg Surg (2012) 0.85
Recombinant factor VIIa is associated with an improved 24-hour survival without an improvement in inpatient survival in massively transfused civilian trauma patients. Clinics (Sao Paulo) (2011) 0.79
Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors. J Blood Med (2010) 0.79
Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran. Clinicoecon Outcomes Res (2011) 0.79
Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost (2014) 0.79
Comparison of bypassing agents in bleeding reduction in treatment of bleeding episodes in patients with haemophilia and inhibitors. Iran Red Crescent Med J (2014) 0.78
Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients. Drug Des Devel Ther (2010) 0.77
Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients. Vasc Health Risk Manag (2006) 0.75
Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran. Iran J Pharm Res (2016) 0.75
Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study). Iran J Pathol (2016) 0.75
Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors. J Blood Med (2011) 0.75
Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors. Blood Transfus (2015) 0.75
Postsurgical coagulopathy in a hemophilia A patient with inhibitors: efficacy of recombinant factor VIIa. J Anesth (2014) 0.75
A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med (1989) 4.04
Essential role of LAT in T cell development. Immunity (1999) 3.94
NDR1, a pathogen-induced component required for Arabidopsis disease resistance. Science (1997) 3.16
Lysosome biogenesis requires Rab9 function and receptor recycling from endosomes to the trans-Golgi network. J Cell Biol (1994) 2.95
Factor VIII:C inhibitor associated with monoclonal-antibody purified FVIII concentrate. Lancet (1990) 2.91
The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood (1987) 2.84
Membrane targeting of the small GTPase Rab9 is accompanied by nucleotide exchange. Nature (1994) 2.50
Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. J Lab Clin Med (1992) 2.22
Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood (2001) 1.99
T-lymphocyte subpopulations in patients with classic hemophilia treated with cryoprecipitate and lyophilized concentrates. N Engl J Med (1983) 1.91
The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia (2003) 1.80
Acquired inhibitors. Baillieres Clin Haematol (1996) 1.62
Low-molecular-weight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol (2000) 1.62
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost (2006) 1.62
Treatment of inherited coagulation disorders. Am J Med (1995) 1.60
Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med (1992) 1.57
von Willebrand factor interacts with malignant hematopoietic cell lines: evidence for the presence of specific binding sites and modification of von Willebrand factor structure and function. J Lab Clin Med (1992) 1.54
PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost (1998) 1.48
Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US). Haemophilia (2011) 1.47
Clinical manifestations of the prothrombin G20210A mutation in children: a pediatric coagulation consortium study. J Thromb Haemost (2003) 1.41
Heparin-induced thrombocytopenia in a child. J Pediatr (1992) 1.40
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost (1998) 1.35
Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood (1997) 1.34
Rab-GDI presents functional Rab9 to the intracellular transport machinery and contributes selectivity to Rab9 membrane recruitment. J Biol Chem (1994) 1.33
Circulating coagulation inhibitors in the acquired immunodeficiency syndrome. Ann Intern Med (1986) 1.32
The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding domain. J Clin Invest (1991) 1.26
Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet (1988) 1.24
Plasminogen deficiency. Haemophilia (2008) 1.22
Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. Haemophilia (2011) 1.21
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia (2004) 1.19
Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA. Proc Natl Acad Sci U S A (1989) 1.17
Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. Haemophilia (2011) 1.17
Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood (1986) 1.16
Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study. Lancet (1994) 1.16
Immunobiology of hepatitis C virus (HCV) infection: the role of CD4 T cells in HCV infection. Immunol Rev (2000) 1.15
Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia (2004) 1.14
Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost (2008) 1.11
A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood (1995) 1.11
In vitro correlation of platelet aggregation with occurrence of disseminated intravascular coagulation and subacute bacterial endocarditis. J Lab Clin Med (1987) 1.10
Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia (2015) 1.09
B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study. Haemophilia (2005) 1.07
Acute pulmonary embolism treated with tissue plasminogen activator. Lancet (1986) 1.06
Phenotypic expressions of CCR5-delta32/delta32 homozygosity. J Acquir Immune Defic Syndr (1999) 1.05
Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J Thromb Haemost (2013) 1.05
Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost (2009) 1.02
Plasminogen activator inhibitor type 1 deficiency. Haemophilia (2008) 1.02
Microwave technology for the rapid thawing of frozen blood components. Am J Clin Pathol (1985) 1.00
Critical von Willebrand factor A1 domain residues influence type VI collagen binding. J Thromb Haemost (2012) 0.98
Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease. J Thromb Haemost (2012) 0.98
Interactions between von Willebrand factor and Factor VIII: where did they first meet. J Pediatr Hematol Oncol (2000) 0.97
Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia (2004) 0.97
Abnormal T-lymphocyte subpopulations associated with transfusion of blood-derived products. Lancet (1983) 0.96
VERITAS-PRN: a new measure of adherence to episodic treatment regimens in haemophilia. Haemophilia (2009) 0.96
Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia (2001) 0.96
The critical interaction of glycoprotein (GP) IBbeta with GPIX-a genetic cause of Bernard-Soulier syndrome. Blood (1999) 0.96
Incidence of lymphomas and other cancers in HIV-infected and HIV-uninfected patients with hemophilia. JAMA (1992) 0.95
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia (2012) 0.94
Hyponatremia and seizures in young children given DDAVP. Am J Hematol (1989) 0.94
Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres. Haemophilia (2011) 0.94
Bleeding disorders: A common cause of menorrhagia in adolescents. J Pediatr (2001) 0.94
Vitamin K deficiency in the newborn infant: prevalence and perinatal risk factors. J Pediatr (1986) 0.93
Warfarin anticoagulation: difficulties in interpretation of the prothrombin time. Thromb Res (1982) 0.92
Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood (1994) 0.92
Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia (2012) 0.91
Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE). Haemophilia (2011) 0.91
The effect of the absence of rumen ciliate protozoa on growing lambs fed on a roughage-concentrate diet. Br J Nutr (1971) 0.91
Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. Haemophilia (2004) 0.90
Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol (1992) 0.90
Delayed somatic growth and pubertal development in human immunodeficiency virus-infected hemophiliac boys: Hemophilia Growth and Development Study. J Pediatr (1994) 0.89
Thymosin in the early diagnosis and treatment of high risk homosexuals and hemophiliacs with AIDS-like immune dysfunction. Ann N Y Acad Sci (1984) 0.88
Cardiovascular comorbidities are increased in U.S. patients with haemophilia A: a retrospective database analysis. Haemophilia (2013) 0.88
Long-term follow-up of hemophiliacs with lymphocytopenia or thrombocytopenia. Blood (1985) 0.88
Protein C and protein S levels in two patients with acquired purpura fulminans. Br J Haematol (1990) 0.88
D-dimer testing: the role of the clinical laboratory in the diagnosis of pulmonary embolism. J Clin Pathol (2001) 0.88
Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation. Circulation (1990) 0.87
Glanzmann thrombasthenia resulting from a single amino acid substitution between the second and third calcium-binding domains of GPIIb. Role of the GPIIb amino terminus in integrin subunit association. J Clin Invest (1995) 0.87
Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease. Haemophilia (2013) 0.87
Genetic alteration of the D2 domain abolishes von Willebrand factor multimerization and trafficking into storage. J Thromb Haemost (2009) 0.86
Methylene blue for neutralization of heparin. Thromb Res (1989) 0.86
Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders. Haemophilia (2013) 0.86
Coagulant proteins and thrombin generation in synovial fluid: a model for extravascular coagulation. Am J Hematol (1995) 0.85
Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia (2008) 0.85
Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br J Haematol (1982) 0.85
Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. J Thromb Haemost (2009) 0.85
Stimulation of fibrinogen synthesis: a possible functional role of fibrinogen degradation products. Blood (1980) 0.84
Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups. Br J Haematol (1996) 0.84
Inverse correlation between age related abnormalities of T-cell immunity and circulating thymosin alpha 1 levels in haemophilia A. Br J Haematol (1984) 0.84
Hemostatic responses to maximal exercise in oral contraceptive users. Am J Obstet Gynecol (1999) 0.84
Reconstitution of Rab9 endosomal targeting and nucleotide exchange using purified Rab9-GDP dissociation inhibitor complexes and endosome-enriched membranes. Methods Enzymol (1995) 0.84
An unusual cause of cerebral venous thrombosis in a four-year-old child. Stroke (1993) 0.84
Ultrastructural markers in circulating lymphocytes of subjects at risk for AIDS. Am J Clin Pathol (1985) 0.83
The effect of homologous thrombin and fibrinogen degradation products on fibrinogen synthesis in rabbits. J Lab Clin Med (1979) 0.83
Butaclamol hydrochloride (AY-23,028): an early evaluation in severely ill schizophrenics. Dis Nerv Syst (1975) 0.83